BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29492969)

  • 1. Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.
    Abubakar M; Chang-Claude J; Ali HR; Chatterjee N; Coulson P; Daley F; Blows F; Benitez J; Milne RL; Brenner H; Stegmaier C; Mannermaa A; Rudolph A; Sinn P; Couch FJ; Devilee P; Tollenaar RAEM; Seynaeve C; Figueroa J; Lissowska J; Hewitt S; Hooning MJ; Hollestelle A; Foekens R; Koppert LB; ; Bolla MK; Wang Q; Jones ME; Schoemaker MJ; Keeman R; Easton DF; Swerdlow AJ; Sherman ME; Schmidt MK; Pharoah PD; Garcia-Closas M
    Int J Cancer; 2018 Aug; 143(4):746-757. PubMed ID: 29492969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.
    Yang XR; Chang-Claude J; Goode EL; Couch FJ; Nevanlinna H; Milne RL; Gaudet M; Schmidt MK; Broeks A; Cox A; Fasching PA; Hein R; Spurdle AB; Blows F; Driver K; Flesch-Janys D; Heinz J; Sinn P; Vrieling A; Heikkinen T; Aittomäki K; Heikkilä P; Blomqvist C; Lissowska J; Peplonska B; Chanock S; Figueroa J; Brinton L; Hall P; Czene K; Humphreys K; Darabi H; Liu J; Van 't Veer LJ; van Leeuwen FE; Andrulis IL; Glendon G; Knight JA; Mulligan AM; O'Malley FP; Weerasooriya N; John EM; Beckmann MW; Hartmann A; Weihbrecht SB; Wachter DL; Jud SM; Loehberg CR; Baglietto L; English DR; Giles GG; McLean CA; Severi G; Lambrechts D; Vandorpe T; Weltens C; Paridaens R; Smeets A; Neven P; Wildiers H; Wang X; Olson JE; Cafourek V; Fredericksen Z; Kosel M; Vachon C; Cramp HE; Connley D; Cross SS; Balasubramanian SP; Reed MW; Dörk T; Bremer M; Meyer A; Karstens JH; Ay A; Park-Simon TW; Hillemanns P; Arias Pérez JI; Menéndez Rodríguez P; Zamora P; Benítez J; Ko YD; Fischer HP; Hamann U; Pesch B; Brüning T; Justenhoven C; Brauch H; Eccles DM; Tapper WJ; Gerty SM; Sawyer EJ; Tomlinson IP; Jones A; Kerin M; Miller N; McInerney N; Anton-Culver H; Ziogas A; Shen CY; Hsiung CN; Wu PE; Yang SL; Yu JC; Chen ST; Hsu GC; Haiman CA; Henderson BE; Le Marchand L; Kolonel LN; Lindblom A; Margolin S; Jakubowska A; Lubiński J; Huzarski T; Byrski T; Górski B; Gronwald J; Hooning MJ; Hollestelle A; van den Ouweland AM; Jager A; Kriege M; Tilanus-Linthorst MM; Collée M; Wang-Gohrke S; Pylkäs K; Jukkola-Vuorinen A; Mononen K; Grip M; Hirvikoski P; Winqvist R; Mannermaa A; Kosma VM; Kauppinen J; Kataja V; Auvinen P; Soini Y; Sironen R; Bojesen SE; Ørsted DD; Kaur-Knudsen D; Flyger H; Nordestgaard BG; Holland H; Chenevix-Trench G; Manoukian S; Barile M; Radice P; Hankinson SE; Hunter DJ; Tamimi R; Sangrajrang S; Brennan P; McKay J; Odefrey F; Gaborieau V; Devilee P; Huijts PE; Tollenaar RA; Seynaeve C; Dite GS; Apicella C; Hopper JL; Hammet F; Tsimiklis H; Smith LD; Southey MC; Humphreys MK; Easton D; Pharoah P; Sherman ME; Garcia-Closas M
    J Natl Cancer Inst; 2011 Feb; 103(3):250-63. PubMed ID: 21191117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women.
    Cui Y; Deming-Halverson SL; Shrubsole MJ; Beeghly-Fadiel A; Fair AM; Sanderson M; Shu XO; Kelley MC; Zheng W
    Clin Breast Cancer; 2014 Dec; 14(6):417-25. PubMed ID: 24970715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors.
    de Gregorio A; Friedl TWP; Hering E; Widschwendter P; de Gregorio N; Bekes I; Janni W; Dayan D; Huober JB
    Oncology; 2021; 99(12):780-789. PubMed ID: 34535596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population.
    Durrani S; Al-Mushawa F; Heena H; Wani T; Al-Qahtani A
    Ann Diagn Pathol; 2021 Apr; 51():151674. PubMed ID: 33360027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proliferative Index (Ki67) for Prediction in Breast Duct Carcinomas.
    Ahmed ST; Ahmed AM; Musa DH; Sulayvani FK; Al-Khyatt M; Pity IS
    Asian Pac J Cancer Prev; 2018 Apr; 19(4):955-959. PubMed ID: 29693354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of breast cancer risk factors on clinically relevant prognostic biomarkers for primary breast cancer.
    Abubakar M; Guo C; Koka H; Zhu B; Deng J; Hu N; Zhou B; Garcia-Closas M; Lu N; Yang XR
    Breast Cancer Res Treat; 2021 Sep; 189(2):483-495. PubMed ID: 34185195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients.
    Haroon S; Hashmi AA; Khurshid A; Kanpurwala MA; Mujtuba S; Malik B; Faridi N
    Asian Pac J Cancer Prev; 2013; 14(7):4353-8. PubMed ID: 23992002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reproductive factors and risk of hormone receptor positive and negative breast cancer: a cohort study.
    Ritte R; Tikk K; Lukanova A; Tjønneland A; Olsen A; Overvad K; Dossus L; Fournier A; Clavel-Chapelon F; Grote V; Boeing H; Aleksandrova K; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Berrino F; Mattiello A; Tumino R; Sacerdote C; Quirós JR; Buckland G; Molina-Montes E; Chirlaque MD; Ardanaz E; Amiano P; Bueno-de-Mesquita HB; van Gils CH; Peeters PH; Wareham N; Khaw KT; Key TJ; Travis RC; Weiderpass E; Dumeaux V; Lund E; Sund M; Andersson A; Romieu I; Rinaldi S; Vineis P; Merritt MA; Riboli E; Kaaks R
    BMC Cancer; 2013 Dec; 13():584. PubMed ID: 24321460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers.
    Yagi T; Inoue N; Yanai A; Murase K; Imamura M; Miyagawa Y; Enomoto Y; Nishimukai A; Takatsuka Y; Hirota S; Akazawa K; Miyoshi Y
    Breast Cancer; 2016 Mar; 23(2):224-30. PubMed ID: 25082658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer.
    Ueno T; Saji S; Chiba T; Kamma H; Isaka H; Itoh H; Imi K; Miyamoto K; Tada M; Sasano H; Toi M; Imoto S
    Tumour Biol; 2018 Nov; 40(10):1010428318811025. PubMed ID: 30841783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
    Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
    Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: a case-case study.
    Song N; Choi JY; Sung H; Chung S; Song M; Park SK; Han W; Lee JW; Kim MK; Yoo KY; Ahn SH; Noh DY; Kang D
    Int J Cancer; 2014 Aug; 135(3):669-81. PubMed ID: 24916400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survival in breast cancer.
    Kilickap S; Kaya Y; Yucel B; Tuncer E; Babacan NA; Elagoz S
    Asian Pac J Cancer Prev; 2014; 15(3):1381-5. PubMed ID: 24606469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ki-67 is a prognostic marker for hormone receptor positive tumors.
    Pérez-López ME; García-Gómez J; Alves MT; Paradela A; García-Mata J; García-Caballero T
    Clin Transl Oncol; 2016 Oct; 18(10):996-1002. PubMed ID: 26742937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
    Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
    Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parity and age at first childbirth in relation to the risk of different breast cancer subgroups.
    Butt S; Borgquist S; Anagnostaki L; Landberg G; Manjer J
    Int J Cancer; 2009 Oct; 125(8):1926-34. PubMed ID: 19569233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
    Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
    J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancers.
    Yanai A; Miyagawa Y; Murase K; Imamura M; Yagi T; Ichii S; Takatsuka Y; Ito T; Hirota S; Sasa M; Katagiri T; Miyoshi Y
    Int J Clin Oncol; 2014; 19(3):467-72. PubMed ID: 23821234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.